



OxySure Systems, Inc. (OXYS)

1Q 2015 Financial Results

May 19, 2015

It's About Time.

Forward Looking Statements

The following may contain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this communication, including statements relating to our growth strategy, financial results, product approvals, and development programs, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time in our filings with the Securities and Exchange Commission. Our actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors.




First Quarter 2015 Highlights

- Revenues were \$624,514, up 75%
- Eleventh consecutive quarter of sales growth
- Gross profit up 92%
- Gross margin increased by 4%
- Selling, general & administrative expense was \$1.3 million
- Total assets was \$2.2 million
- Capital leases completely extinguished
- Long term debt completely extinguished
- Net loss per share was \$0.05
- Total replacement cartridges as a percentage of the Model 615 installed base was 45%



1Q 2015 Financial Results

Y/Y Results – 1Q15 v 1Q14 (in thousands)



Sales trends

	<u>3Q12</u>	<u>4Q12</u>	<u>1Q13</u>	<u>2Q13</u>	<u>3Q13</u>	<u>4Q13</u>	<u>1Q14</u>	<u>2Q14</u>	<u>3Q14</u>	<u>4Q14</u>	<u>1Q15</u>
Revenues	103,327	75,595	240,420	476,071	545,819	538,017	356,228	678,112	818,456	584,606	624,514
Revenue Growth	81,822	10,441	212,041	412,985	442,492	462,422	115,808	202,041	272,637	46,589	268,285
Growth%	380%	16%	747%	655%	428%	612%	48%	42%	50%	9%	75%


Annual revenues

	<u>FY2012</u>	<u>FY2013</u>	<u>FY2014</u>
Revenues	269,697	1,800,327	2,437,402
Revenue Growth	84,488	1,530,630	637,075
Growth%	46%	568%	35%



1Q 2015 Financial Results

Y/Y Results – 1Q15 v 1Q14 (in thousands)



FY 2014 Financial Results - 12 Months

Y/Y Results – 1Q15 v 1Q14 (in thousands)

1Q 2015	1Q 2014
Revenues:	
\$624,514	\$356,229
Net income (loss):	
\$(1,340,103)	\$(376,320)
Net income (loss) per share:	
\$(.05)	\$(.01)
EBITDA per share	
\$(709,494) / \$(.02)	\$(160,796) / \$(.01)



Replacement cartridge sales



OxySure Model 615, US version



Replacement cartridge for OxySure Model 615



OxySure Model 615, Europe version



Open the Lid



Remove Expended Cartridge



Replace with New Cartridge & Remove Safety Tabs

Sales Build Out

- Added great distribution partners
- Keen discussions on international front
- Great progress with recruitment and training
- 5-6 Territory Managers per incoming class
- Not yet reflected in 1Q15 revenues
- 3-6 Month ramp
- Target sales per Territory Manager approx. \$500,000 pa
- Targeting between 25 and 30 TMs by end of 2015



Resuscitation Division Products



What can we look forward to..

- Acceleration of sales ramp as direct sales headcount increases
- Partnership/Licensing deals
- International deals
- Direct to Consumer campaign
- Acceleration of awareness building
- Staffing additions
- New products
- Uplisting



Summary

- On track with our focus on growth
- Building new, stronger momentum
- Remain focused on building strong fundamentals

1Q 2015 Financial Results

OxySure Systems, Inc. (OXYS)

investors@oxysure.com

www.oxysure.com

Questions & Answers



Contact Information

OxySure Systems, Inc.

OXYS: OTCQB

10880 John W. Elliott Road, Suite 600

Frisco, TX 75034 USA

Tel: (+1) 972-294-6450

info@oxysure.com

www.OxySure.com



Redchip Companies, Inc.

800-733-2447, ext. 107

jon@redchip.com

www.redchip.com/

Renmark Financial Communications, Inc.

(416) 644-2020

Bettina Filippone: bfilippone@renmarkfinancial.com

Richard Dupuy: rdupuy@renmarkfinancial.com

www.renmarkfinancial.com/

